Morphine Sulfate tablets

Morphine Sulfate tablets

Form: Oral Tablets

Strength: 15 mg, 30 mg, 60 mg, 100 mg

Reference Brands: MS Contin(US & EU)

Category: Analgesic

Morphine sulfate tablets are approved in the US and EU for severe pain management, including post-surgical and cancer pain. In the US, brands like MS Contin are regulated by the FDA, supported by dossiers demonstrating safety, efficacy, and strict manufacturing standards. In the EU, similar approvals are governed by EMA, requiring comprehensive dossiers and pharmacovigilance commitments. Both regions enforce strict control due to the drug’s high abuse potential and dependance risks. For regulatory dossier preparation, compliance, and registration assistance, visit PharmaTradz. We support seamless market entry for morphine sulfate tablets, ensuring adherence to European and American standards for safe, effective opioid therapy while navigating complex regulatory landscapes effectively.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Dexketoprofen + Tramadol tablets

Strength: 25 mg dexketoprofen + 37.5 mg tramadol

Form: Tablets

Reference Brands: Enantyum(EU)

View Details Get Enquiry
Paracetamol + Codeine tablets

Strength: 300 mg paracetamol + 30 mg codeine; 300 mg + 60 mg

Form: Tablets

Reference Brands: Tylenol with Codeine(US)

View Details Get Enquiry
Aceclofenac + Paracetamol tablets

Strength: 100 mg Aceclofenac + 325 mg Paracetamol

Form: Tablets

Reference Brands: Generic formulations marketed under different names

View Details Get Enquiry
Tramadol + Paracetamol tablets

Strength: 37.5 mg tramadol + 325 mg paracetamol; 75 mg + 650 mg

Form: Oral Tablets

Reference Brands: Ultracet(US); Tramacet(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more